A 12-week randomized trial of a specific whole-fruit bergamot extract (Brumex, 400 mg/day) in 50 moderately hypercholesterolemic adults reported significant reductions in total cholesterol, triglycerides, LDL-C, non-HDL-C, apolipoprotein B100, fasting glucose and liver enzymes versus placebo. A companion cell-culture experiment found the extract activated AMPK and reduced lipid-synthesis gene expression in HepG2 cells. It did not measure prevention of heart attacks or protection from anabolic-steroid injury, and the cell-culture finding does not by itself prove the human mechanism.[1]
- Product-specific (Brumex) short trial with surrogate laboratory outcomes; in-vitro AMPK/HepG2 findings do not prove the human mechanism, and funding/conflict-of-interest disclosures for this branded ingredient were not confirmed from the abstract.
- Abstract-checked; no qualified clinical review.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.
· Reopened the PubMed structured abstract via E-utilities and added the full list of significantly changed lipid/liver measures and the AMPK mechanism detail. No PMC full text available; funding disclosure for the Brumex ingredient remains an open gap. Independent editorial review pending; no qualified clinical review.